NasdaqGS - Delayed Quote USD

Amneal Pharmaceuticals, Inc. (AMRX)

7.62

+0.45

+(6.28%)

At close: June 6 at 4:00:01 PM EDT

7.70

+0.08

+(1.05%)

After hours: June 6 at 5:26:56 PM EDT

No Tool

Measure

Undo

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for AMRX

Amneal to Participate at Upcoming Investor Conferences in June

Amneal to Participate at Upcoming Investor Conferences in June

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ...

Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ...

Amneal Reports First Quarter 2025 Financial Results

Amneal Reports First Quarter 2025 Financial Results

Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years

Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

Amneal to Report First Quarter 2025 Results on May 2, 2025

Amneal to Report First Quarter 2025 Results on May 2, 2025

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

RDY Dr. Reddy's Laboratories Limited

15.55

+0.13%

CPIX Cumberland Pharmaceuticals Inc.

5.82

+7.92%

HLN Haleon plc

11.07

-0.45%

HCM HUTCHMED (China) Limited

15.35

+0.59%

ANIK Anika Therapeutics, Inc.

11.35

+1.43%

LFCR Lifecore Biomedical, Inc.

6.85

+1.48%

ALVO Alvotech

10.66

+1.52%

ELAN Elanco Animal Health Incorporated

13.90

+3.50%

ALKS Alkermes plc

31.71

+2.29%

AMPH Amphastar Pharmaceuticals, Inc.

25.99

+1.84%